BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1148 related articles for article (PubMed ID: 26490331)

  • 1. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The calpain-suppressing effects of olesoxime in Huntington's disease.
    Weber JJ; Ortiz Rios MM; Riess O; Clemens LE; Nguyen HP
    Rare Dis; 2016; 4(1):e1153778. PubMed ID: 27141414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.
    Eckmann J; Clemens LE; Eckert SH; Hagl S; Yu-Taeger L; Bordet T; Pruss RM; Muller WE; Leuner K; Nguyen HP; Eckert GP
    Mol Neurobiol; 2014 Aug; 50(1):107-18. PubMed ID: 24633813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate.
    Weber JJ; Clemensson LE; Schiöth HB; Nguyen HP
    Biochem Pharmacol; 2019 Oct; 168():305-318. PubMed ID: 31283931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
    Gray M; Shirasaki DI; Cepeda C; André VM; Wilburn B; Lu XH; Tao J; Yamazaki I; Li SH; Sun YE; Li XJ; Levine MS; Yang XW
    J Neurosci; 2008 Jun; 28(24):6182-95. PubMed ID: 18550760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
    Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calpain activation in Huntington's disease.
    Gafni J; Ellerby LM
    J Neurosci; 2002 Jun; 22(12):4842-9. PubMed ID: 12077181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease.
    Weber JJ; Kloock SJ; Nagel M; Ortiz-Rios MM; Hofmann J; Riess O; Nguyen HP
    Neuropharmacology; 2018 May; 133():94-106. PubMed ID: 29355642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.
    Bizat N; Hermel JM; Boyer F; Jacquard C; Créminon C; Ouary S; Escartin C; Hantraye P; Kajewski S; Brouillet E
    J Neurosci; 2003 Jun; 23(12):5020-30. PubMed ID: 12832525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits.
    Aharony I; Ehrnhoefer DE; Shruster A; Qiu X; Franciosi S; Hayden MR; Offen D
    Hum Mol Genet; 2015 May; 24(9):2604-14. PubMed ID: 25616965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus.
    Gafni J; Hermel E; Young JE; Wellington CL; Hayden MR; Ellerby LM
    J Biol Chem; 2004 May; 279(19):20211-20. PubMed ID: 14981075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
    Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
    J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.
    Chang DT; Rintoul GL; Pandipati S; Reynolds IJ
    Neurobiol Dis; 2006 May; 22(2):388-400. PubMed ID: 16473015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
    Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
    J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington disease and the huntingtin protein.
    Zheng Z; Diamond MI
    Prog Mol Biol Transl Sci; 2012; 107():189-214. PubMed ID: 22482451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.